Like a lot of players in the healthcare industry, it's a popular move to grow your offerings by acquiring other companies, and there have been thousands of such acquisition over the past few decades.
Clementia Pharmaceuticals' (CMTA) primary drug development is called Palovarotene, which is a Retinoic Acid Receptor Gamma (RARy). This reduces BMP signaling, inhibiting SMAD degradation for people suffering from Fibrodysplasia Ossificans Progressiva, or FOP - a disease that creates heterotopic bone formations where healthy tissue should be, severely limiting overall movement and ultimately leading to an early death.